{"disease":{"id":"kras-g12v","name":"kras g12v"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06545201","title":"RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT07342738","title":"TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":25,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05631899","title":"CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT07083479","title":"Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Elicio Therapeutics","has_results":false},{"nct_id":"NCT05389514","title":"Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors","phase":"","overall_status":"TEMPORARILY_NOT_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Providence Health & Services","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}